Woodbine, MD, July 25, 2022–Rithim Biologics®, Inc. is excited to announce the issuance of its first patent, US 11,369,773 B2, covering TARGETED CARDIAC THERAPY using the company’s proprietary DAAViS Catheter™. The present invention relates to a targeted cardiac therapy device that can precisely deliver therapeutic compounds to desired locations on, around or within the heart of a patient, and methods of treating conduction system disease, sinus node dysfunction, atrial fibrillation, myocardial infarction, and heart failure, by delivering genetically engineered vectors or cells, proteins, stem cells, small molecule pharmaceuticals and biologics.
J. Kevin Donahue, M.D., co-Founder of Rithim Biologics and a named inventor of the patent stated: “we are pleased with this patent issuance for the DAAViS catheter as it aids in providing future advanced tools for delivery of gene therapies to the heart’s surface in a less invasive technique.”
Ronald L. Anderson, President and co-founder of Rithim, noted: “this patent represents another large step forward in Rithim’s development as a company and for potential future treatment options for patients with rhythm disturbances such as atrial fibrillation, a $ 6 billion annual US healthcare burden.”
Rithim Biologics®, Inc. is a privately held, early-stage startup company developing surgical tools and kits for delivering gene therapies to treat tachycardias (fast heart rates) in humans. Initial efforts are targeting atrial fibrillation (AF) and more specifically those patients at risk for post-operative (cardiac) AF (POAF) combining KCNH2-G628 gene therapy development with proprietary instrumentation and kits for efficacious delivery in humans.
For further information contact: randerson@rithimbiologics.com
